
Company Overview
Company Type: Public Company
Website: groupedevonian.com
Number of Employees: -
Ticker: GSD (TSXV)
Year Founded: 2015


Business Description
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. The company was incorporated in 2015 and is headquartered in Québec, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
1.9
Market Capitalization
22.0
TEV/Total Revenue
10.9x
EBITDA
(3.8)
Total Enterprise Value
20.6
TEV/EBITDA
NM
EBIT
(4.2)
Cash & ST Invst.
5.1
P/Diluted EPS Before Extra
NM
Net Income
(4.5)
Total Debt
3.7
Price/Tang BV
5.6x
Capital Expenditure
0.0
Total Assets
18.8
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Apr-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023

Key Professionals
Name
Title
Montanaro, Pierre J.
President, CEO & Director
Laurin, Colette 
Interim CFO, Corporate Secretary & Corporate Controller
Boulet, Andre P.
Chief Scientific Officer & Director

Key Board Members
Name
Title
Montanaro, Pierre J.
President, CEO & Director
Boulet, Andre P.
Chief Scientific Officer & Director
Baker, David C.
Independent Director
Chabria, Ashish B.
Independent Director
Dahl, Edouard 
Independent Director
Flamand, Louis 
Member of Scientific Advisory Board & Independent Director
Forcione, Jean 
Independent Director
Gregoire, Luc D.
Independent Director
Hanna, Sam 
Member of Clinical Dermatology Advisory Board
Jabaji, Suha 
Member of Scientific Advisory Board
Landells, Ian D. R.
Member of Clinical Dermatology Advisory Board
Malouin, Francois 
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
360, rue des Entrepreneurs Montmagny | Québec, QC | G5V 4T1 | Canada

Current and Pending Investors
Aspri Pharma Canada Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.15
Market Cap (mm)
22.0
Open
 0.17
Shares Out. (mm)
146.7
Previous Close
 0.15
Float %
84.5%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.18/ 0.15
Diluted EPS Excl. Extra Items
(0.04)
52 wk High/Low
 0.44/ 0.13
P/Diluted EPS Before Extra
NM
Volume (mm)
0.01
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
2.04


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Altius Healthcare Inc.
Altius Healthcare Inc. engages in producing, importing, marketing, and distributing generic medicines. The company is based in Concord, Canada. As of February 1, 2018, Altius Healthcare Inc. operates as a subsidiary of Devonian Health Group Inc.

United States and Canada
Pharmaceuticals
-
-
-
All the Assets of PurGenesis
As of April 30, 2015, All the Assets of PurGenesis was acquired by Devonian Health Group Inc.

United States and Canada
-
-
-
-
Orletto Capital Inc.
As of May 15, 2017, Devonian Health Group Inc. was acquired by Devonian Health Group Inc., in a reverse merger transaction. Orletto Capital Inc. does not have significant operations. The company intends to identify and evaluate assets or businesses with a view to complete a qualifying transaction. Orletto Capital Inc. was incorporated in 2013 and is based in Quebec, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-01-2023
Sep-01-2023
Private Placement
Target
Devonian Health Group Inc. (TSXV:GSD)


0.37
May-19-2023
Jun-06-2023
Private Placement
Target
Devonian Health Group Inc. (TSXV:GSD)


0.89
May-10-2023
-
Shelf Registration
Target
Devonian Health Group Inc. (TSXV:GSD)


22.44
Nov-12-2021
Nov-30-2021
Private Placement
Target
Devonian Health Group Inc. (TSXV:GSD)


7.84
Sep-13-2021
Sep-13-2021
Private Placement
Target
Devonian Health Group Inc. (TSXV:GSD)


0.84
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-01-2023
Private Placements
Devonian Health Group Inc. announced that it has received CAD 0.5 million in funding
Jun-06-2023
Private Placements
Devonian Health Group Inc. announced that it has received CAD 1.199665 million in funding
May-19-2023
Private Placements
Devonian Health Group Inc. announced that it expects to receive CAD 5 million in funding
May-16-2023
Product-Related Announcements
Devonian Health Group Announces Presentation of ThykamineTM Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides ThykamineTM Clinical Development Program Update
May-12-2023
Executive/Board Changes - Other
Devonian Health Group Announces the Appointment of New Board Members

M&A Advisors
Stein Monast L.L.P.


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Stein Monast L.L.P.
Private Placement Advisors
Raymond James Ltd.


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Wright Investors' Service Inc.

May 24, 2023 01:41 AM
GSD
Flow of Funds Report for Devonian Health Group Inc - prepared by Wright Investors Service
Notes
69
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Apr 13, 2023 06:00 PM
GSD
Rating Update for Devonian Health Group Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Dec 21, 2022 05:00 PM
GSD
Rating Update for Devonian Health Group Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jun 23, 2022 07:21 AM
GSD
Rating Update for Devonian Health Group Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Apr 21, 2022 07:20 AM
GSD
Rating Update for Devonian Health Group Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Dec 07, 2020 05:00 PM
GSD
Rating Update for Devonian Health Group Inc
EPS Estimates*
3
Infinata, Inc.
Infinata Research
Nov 03, 2020 08:35 AM
GSD
Devonian Health Group Inc. - Company Report
Reports
11
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Oct 26, 2020 07:51 AM
GSD
Rating Update for Devonian Health Group Inc
EPS Estimates*
3
Infinata, Inc.
Infinata Research
Sep 03, 2020 04:05 AM
GSD
Devonian Health Group Inc. - Company Report
Reports
11
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 19, 2020 06:00 PM
GSD
Rating Update for Devonian Health Group Inc
EPS Estimates*
3


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


9099-3452 Québec Inc

19,965,536

13.61

3.0

Feb-03-2023


Dahan, Sybil 

1,516,553

1.03

0.2

Feb-03-2023


Forcione, Jean 

666,667

0.45

0.1

Jun-06-2023


Montanaro, Pierre J.

299,999

0.20

0.0

Jun-06-2023


Boulet Ph.D., Andre P.

84,320

0.06

0.0

Feb-03-2023


Fiducie Familiale Sybil Dahan

80,622

0.05

0.0

Feb-03-2023


Longgrass Marketing Inc

41,000

0.03

0.0

Feb-03-2023


Laurin C.A., CPA, Colette 

33,333

0.02

0.0

Feb-03-2023


Fretz, Terry Lynn

15,866

0.01

0.0

Feb-03-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Forcione, Jean 
666,667
666,667
Montanaro, Pierre J.
299,999
133,333

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Botanical Drugs, Purgenesis, Sun-Care Products (Future), Thykamine (Future)


Upcoming Events
Date/Time
Type
Nov-24-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Language
Size
Sep-01-2023
-
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
News Releases
English
78 KB
Sep-01-2023
-
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
News Releases
French
160 KB
Jun-28-2023
Apr-30-2023
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
Interim Financial Statements
French
482 KB
Jun-28-2023
Apr-30-2023
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
Interim Financial Statements
English
464 KB
Jun-26-2023
-
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
Shelf Prospectus (NI 44-102)
English
388 KB
Jun-22-2023
-
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
Shelf Prospectus (NI 44-102)
English
8 MB
Jun-22-2023
-
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
Shelf Prospectus (NI 44-102)
English
3 MB
Jun-22-2023
-
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
Shelf Prospectus (NI 44-102)
English
2 MB
Jun-22-2023
-
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
Shelf Prospectus (NI 44-102)
French
456 KB
Jun-22-2023
-
Devonian Health Group Inc. (TSXV:GSD)
SEDAR
Shelf Prospectus (NI 44-102)
English
74 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Forcione, Jean  (Independent Director)
Jun-06-2023
Subordinate Voting Shares
666,667
101,386
Private Acquisition
New
Multiple
Montanaro, Pierre J. (President, CEO & Director)
Jun-06-2023
Subordinate Voting Shares
133,333
20,277
Private Acquisition
80.00
Multiple
Boulet Ph.D., Andre P. (Chief Scientific Officer & Director)
Jan-26-2023
Subordinate Voting Shares
50,000
6,110
Derivative Exercise and Retained Stock
145.69
Multiple
Boulet Ph.D., Andre P. (Chief Scientific Officer & Director)
Apr-19-2022
Multiple Voting Shares
(987)
-
Other Disposition
(100.00)
Multiple
Boulet Ph.D., Andre P. (Chief Scientific Officer & Director)
Apr-19-2022
Subordinate Voting Shares
987
-
Derivative Exercise and Retained Stock
2.96
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Montanaro, Pierre J.
President, CEO & Director
-
-

Boulet, Andre P.
Chief Scientific Officer & Director
-
(514) 288-7489
apboulet@groupedevonian.com
Baker, David C.
Independent Director
-
-

Chabria, Ashish B.
Independent Director
212-909-9001
212-909-9020
Ashish.Chabria@mizuhocbus.com
Dahl, Edouard 
Independent Director
-
-

Flamand, Louis 
Member of Scientific Advisory Board & Independent Director
-
-

Forcione, Jean 
Independent Director
-
-

Gregoire, Luc D.
Independent Director
-
-

Hanna, Sam 
Member of Clinical Dermatology Advisory Board
-
-
-
Jabaji, Suha 
Member of Scientific Advisory Board
-
-
-
Landells, Ian D. R.
Member of Clinical Dermatology Advisory Board
-
-
-
Malouin, Francois 
Member of Scientific Advisory Board
-
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Montanaro, Pierre J.
President, CEO & Director
-
-

Laurin, Colette 
Interim CFO, Corporate Secretary & Corporate Controller
-
-

Boulet, Andre P.
Chief Scientific Officer & Director
-
(514) 288-7489
apboulet@groupedevonian.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
